https://www.bioworld.com/rss en-us Shanghai Zheye Biotechnology LLC has discovered new phenylpropionic acid derivatives acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors potentially useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis. http://www.bioworld.com/articles/732345 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732345-shanghai-zheye-biotechnology-patents-new-apoa-apob-interaction-inhibitors Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have synthesized new GTPase KRAS G12C mutant inhibitors potentially useful for the treatment of cancer, autoimmune disorders and inflammatory disorders. http://www.bioworld.com/articles/732344 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732344-adlai-nortye-discloses-new-kras-g12c-inhibitors Monte Rosa Therapeutics AG has reported new molecular glue degraders comprising an E3 ubiquitin-protein ligase-binding moiety acting as E3 G1/S-specific cyclin-E1 (CCNE1)/cereblon interaction inducers and CCNE1 degradation inducers potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732343 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732343-monte-rosa-therapeutics-divulges-new-ccne1-targeting-degraders Bayer AG has patented new potassium channel Kir3.4 (GIRK4; KCNJ5) and/or Kir3.1/3.4 (GIRK1/4; KCNJ3/5) blockers potentially useful for the treatment of heart failure, arrhythmia, primary hyperaldosteronism and hypertension. http://www.bioworld.com/articles/732342 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732342-bayer-discovers-new-potassium-channel-blockers Sun Pharmaceutical Advanced Research Co. Ltd. has divulged new macrocyclic ATM kinase inhibitors potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732341 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732341-sun-pharmaceutical-synthesizes-new-atm-kinase-inhibitors MED-EL Elektromedizinische Geräte GmbH has acquired two gene therapy programs from Rescue Hearing Inc. for genetic hearing and balance disorders. http://www.bioworld.com/articles/732337 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732337-med-el-acquires-gene-therapy-programs-from-rescue-hearing Hand cupping ear to illustration hearing loss A team at the University of California, Los Angeles (UCLA) found that injured kidneys produce ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1), a protein that hydrolyzes extracellular ATP into AMP and pyrophosphate, and that impedes tissue repair. http://www.bioworld.com/articles/732336 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732336-targeting-enpp1-improves-repair-after-acute-kidney-injury Kidneys Researchers at East China Normal University and collaborators reported the discovery and optimization of a series of SUCNR1 antagonists for cancer immunotherapy. http://www.bioworld.com/articles/732335 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732335-sucnr1-antagonist-reverses-tumor-immune-suppression 3D Rendering of tumor microenvironment Aptevo Therapeutics Inc. has been awarded a $1.5 million research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling work for APVO-451, Aptevo’s trispecific antibody-like immunotherapy candidate for solid tumors. http://www.bioworld.com/articles/732334 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732334-grant-supports-aptevos-immunotherapy-apvo-451-for-solid-tumors Illustration of cancer cell in crosshairs being destroyed Flare Therapeutics Inc. has closed an $85 million series C financing and completed a strategic review of its pipeline, with funds being channeled to advance the prioritized programs. http://www.bioworld.com/articles/732333 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732333-flare-therapeutics-to-focus-on-ar-on-degrader-fx-111 Telum Therapeutics SL has completed an €18 million (US$24 million) series A financing to advance its lead program targeting hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by the multidrug-resistant gram-negative pathogen Acinetobacter baumannii. Acinetobacter baumannii.]]> http://www.bioworld.com/articles/732332 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732332-telum-therapeutics-advances-antimicrobials-with-series-a-funding Euro symbol in piggy bank Trex Bio Inc. has disclosed that its development candidate TRB-071, currently in IND-enabling studies, is a CD30 agonist antibody. The approach could have therapeutic potential in inflammatory bowel disease and other autoimmune and inflammatory diseases. http://www.bioworld.com/articles/732331 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732331-trex-bio-discloses-trb-071-as-cd30-agonist-antibody Illustration of intestines with inflammation Researchers at Duke University have demonstrated that retinal endothelial cells (RECs) generated from human pluripotent stem cells can restore retinal vascularization in a preclinical model of ischemic retinal injury. http://www.bioworld.com/articles/732330 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732330-lab-grown-retinal-endothelial-cells-repair-eye-vasculature Illustration demonstrating structure of the human eye and organization of retinal cells At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and Psychiatry (NCNP) showcased how human organoid technologies are reshaping the study of neurodevelopmental vulnerability, addiction and psychiatric disorders. http://www.bioworld.com/articles/732329 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732329-cinp-2026-organoids-reveal-autism-and-addiction-mechanisms AI-generated image for brain organoid neural research Hexapharmatec Co. Ltd. has discovered new transcription factor EB (TFEB) inducers described as potentially useful for the treatment of colitis, kidney and hepatic fibrosis. http://www.bioworld.com/articles/732324 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732324-hexapharmatec-identifies-new-tfeb-inducers Merck Sharp & Dohme LLC (MSD) has synthesized new protein zer-1 homolog (Hzyg, ZER1) ligands potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732323 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732323-hzyg-ligands-disclosed-in-msd-patent Yaoya Technology (Shanghai) Co. Ltd. has discovered new pyrimidothiopyrandione GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732322 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732322-yaoya-technology-identifies-new-kras-g12d-mutant-inhibitors Blueprint Medicines Corp. has identified new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 4 (CDK4)-targeting moiety potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732321 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732321-blueprint-medicines-reports-new-cdk4-degrader-protacs Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized new Kelch-like ECH-associated protein 1 (KEAP1) activators and nuclear factor erythroid 2-related factor 2 (NRF2) degradation inducers potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732320 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732320-sichuan-kelun-biotech-discloses-new-keap1-activators-and-nrf2-degradation-inducers Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone (GH), does not contain GH sequence and selectively activates human GHR for the treatment of GH deficiency (GHD). It is designed to enable once-every-4-week dosing. http://www.bioworld.com/articles/732314 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732314-gensci-134-a-long-acting-growth-hormone-receptor-agonist-fusion-protein 3D illustration of human growth hormone molecules Human growth hormone. A Biotech Co. Ltd., a subsidiary of CDW Holding Ltd., and Neoregen Biotech Co. Ltd. have obtained promising results from in vivo murine testing of LNP-LANFA, a next-generation lipid nanoparticle (LNP) technology under joint development. http://www.bioworld.com/articles/732313 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732313-cdw-reports-in-vivo-results-for-lnp-lanfa 3D concept image of nanoparticle layers Spinal cord traumatic injury can lead to loss of motor function and progressive development of muscle spasticity and rigidity. Researchers from the University of California San Diego and collaborating institutions investigated a novel gene-delivery-based antispasticity strategy. http://www.bioworld.com/articles/732312 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732312-preclinical-study-of-subpial-aav-gad65-vgat-delivery-for-spinal-injury-induced-spasticity Digital spine concept art Smartbax GmbH has announced the successful second closing of its pre-series A financing round for a total of €6.3 million (US$7.2 million) as it advances development of next-generation antibiotics against multidrug-resistant bacteria. http://www.bioworld.com/articles/732311 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732311-smartbax-raises-additional-funds-to-advance-antibiotic-pipeline Illustration of medical professionals, research A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell engager (TCE) for autoimmune disorders in a potential $1.62 billion deal. http://www.bioworld.com/articles/732310 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732310-deerfield-backed-boulevard-metis-pen-16b-trispecific-tce-deal Handshake, businessmen holding dollar sign, lightbulb Predominantly expressed in the striatum, a brain region involved in cognition, motivation and motor control, G protein-coupled receptor 52 (GPR52) regulates dopaminergic and glutamatergic signaling pathways implicated in psychiatric disorders. http://www.bioworld.com/articles/732309 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732309-novel-gpr52-agonist-shows-antipsychotic-like-effects It is known that bacterial cells exchange biological matter, but it is not clear whether bacteria can exchange functional proteins. In a recent paper published in Science on June 25, 2026, researchers from Baylor College of Medicine and their collaborators investigated horizontal protein transfer between bacteria, specifically between protein-donor Escherichia coli and protein-receiving E. coli that could turn into persister cells and tolerate lethal antibiotic doses or a stressful environment. Science on June 25, 2026, researchers from Baylor College of Medicine and their collaborators investigated horizontal protein transfer between bacteria, specifically between protein-donor Escherichia coli and protein-receiving E. coli that could turn into persister cells and tolerate lethal antibiotic doses or a stressful environment.]]> http://www.bioworld.com/articles/732308 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732308-antibiotics-spur-protein-transfer-that-boosts-bacterial-survival Petri dish and capsules lynn.yoffee@clarivate.com Awards are an honor, but they are not why we do what we do. That's why this year's recognition from the APEX Awards is especially meaningful. BioWorld earned seven 2026 APEX Awards, including three Grand Awards and four Awards of Excellence. Judged by publishing industry peers, these honors recognize excellence across reporting, writing, visual storytelling and editorial collaboration. While we are proud of this recognition, what makes it especially rewarding is that it reflects the work our team does every day to serve the global life sciences community. 2026 APEX Awards, including three Grand Awards and four Awards of Excellence. Judged by publishing industry peers, these honors recognize excellence across reporting, writing, visual storytelling and editorial collaboration. While we are proud of this recognition, what makes it especially rewarding is that it reflects the work our team does every day to serve the global life sciences community.]]> http://www.bioworld.com/articles/732328 Tue, 30 Jun 2026 08:00:00 -0400 https://www.bioworld.com/articles/732328-celebrating-recognition-reaffirming-our-mission Award ribbon icon Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd. has reported new CDK4/cyclin D1 inhibitors potentially useful for the treatment of breast cancer. http://www.bioworld.com/articles/732220 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732220-shandong-simcere-medgenn-bio-pharmaceutical-divulges-new-cdk4-cyclin-d1-inhibitors Beijing Earthwise Technology Co. Ltd. has patented new molecular glue degraders comprising an E3 ubiquitin-protein ligase-binding moiety acting as E3 ligase/proto-oncogene Vav (VAV1) interaction inducers and VAV1 degradation inducers. http://www.bioworld.com/articles/732219 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732219-beijing-earthwise-technology-discovers-new-e3-ligase-vav1-interaction-inducers Boyuan Pharmaceutical (Suzhou) Co. Ltd. has divulged new pyridone derivatives potentially useful for the treatment of HIV infection. http://www.bioworld.com/articles/732218 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732218-anti-hiv-compounds-reported-in-boyuan-pharmaceutical-patent